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Long non-coding RNAs (lncRNAs) are transcripts of >200 nucleotides that are not
translated into functional proteins. Cellular lncRNAs have been shown to act as regulators
by interacting with target nucleic acids or proteins and modulating their activities. We
investigated the role of RNA1.2, which is one of four major lncRNAs expressed by human
cytomegalovirus (HCMV), by comparing the properties of parental virus in vitrowith those
of deletion mutants lacking either most of the RNA1.2 gene or only the TATA element
of the promoter. In comparison with parental virus, these mutants exhibited no growth
defects and minimal differences in viral gene expression in human fibroblasts. In contrast,
76 cellular genes were consistently up- or down-regulated by the mutants at both the
RNA and protein levels at 72 h after infection. Differential expression of the gene most
highly upregulated by the mutants (Tumor protein p63-regulated gene 1-like protein;
TPRG1L) was confirmed at both levels by RT-PCR and immunoblotting. Consistent with
the known ability of TPRG1L to upregulate IL-6 expression via NF-κB stimulation, RNA1.2
mutant-infected fibroblasts were observed to upregulate IL-6 in addition to TPRG1L.
Comparable surface expression of TNF receptors and responsiveness to TNF-α in cells
infected by the parental and mutant viruses indicated that activation of signaling by
TNF-α is not involved in upregulation of IL-6 by the mutants. In contrast, inhibition
of NF-κB activity and knockdown of TPRG1L expression reduced the extracellular
release of IL-6 by RNA1.2 mutant-infected cells, thus demonstrating that upregulation
of TPRG1L activates NF-κB. The levels of MCP-1 and CXCL1 transcripts were also
increased in RNA1.2 mutant-infected cells, further demonstrating the presence of active
NF-κB signaling. These results suggest that RNA1.2 plays a role in manipulating intrinsic
NF-κB-dependent cytokine and chemokine release during HCMV infection, thereby
impacting downstream immune responses.
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INTRODUCTION
Long non-coding RNAs (lncRNAs) are transcripts of >200
nucleotides (nt) that do not encode functional proteins.
Instead, they may perform regulatory roles by binding to a
variety of molecules: interacting with DNA or RNA through
complementary base-pairing, or folding into specific secondary
structures that bind to proteins. A wide range of mechanisms
of operation have been identified for the cellular lncRNAs that
have been examined in detail [for reviews: Fatica and Bozzoni,
2014; DiStefano, 2018; Font-Cunill et al., 2018; Hu et al., 2018].
These include modulating RNA processing (such as splicing,
editing and decay) or translation by binding to DNA or RNA,
acting as competing endogenous RNAs by sequestering miRNAs
from their targets, and modulating the ability of proteins to
localize, function or form complexes. Transcriptional regulation
is a prominent cellular process that lncRNAs are known to
modulate. They may recruit chromatin-modifying enzymes to
specific promoters, resulting in modifications of the associated
histones that cause transcriptional activation or inhibition.
They may tether transcription factors to specific promoters, or,
conversely, block transcription factor binding by interacting with
either the binding site or the transcription factor. Also, they
may open up the chromatin structure by binding to promoter
sequences, thereby increasing the accessibility of chromatin to
transcription factors.
The association of lncRNA dysregulation with numerous
diseases, in particular cancerous, cardiovascular and
neurogenerative conditions (DiStefano, 2018), indicates
that the regulation of biological processes by cellular lncRNAs
is crucial [LncRNADisease database: Chen et al., 2013]. Given
the evident importance of lncRNAs and the wide range of
regulatory mechanisms that they employ, it is not surprising
that viruses express their own lncRNAs. Indeed, lncRNAs have
been identified in the large double-stranded DNA viruses of
all three subfamilies of the family Herpesviridae, and those
that have been studied in detail appear to play important
roles. An example is the latency-associated transcript (LAT)
of the alphaherpesvirus herpes simplex virus type 1 (HSV-
1), which plays key roles during infection, including that of
maintaining latency by inhibiting lytic gene expression and
thereby suppressing virus reactivation (Nicoll et al., 2016). The
polyadenylated nuclear (PAN) RNA of the gammaherpesvirus
Kaposi’s sarcoma-associated herpesvirus can also regulate
gene expression by two different routes: interfering with the
expression of immune response factors, and driving lytic gene
expression during reactivation [reviewed in Rossetto and Pari,
2014]. The betaherpesvirus human cytomegalovirus (HCMV),
which is the pathogen of interest in the present study, encodes
four major lncRNAs (RNA2.7, RNA1.2, RNA4.9, and RNA5.0;
the numbers correspond to the approximate sizes of primary
transcripts in kb) in addition to at least 170 protein-coding genes.
Since these lncRNA genes do not significantly overlap protein-
coding genes and encode the majority (65.1%) of polyadenylated
transcripts in infected fibroblasts at 72 h post infection (h p.i.)
(Gatherer et al., 2011; Davison et al., 2013), it seems likely that
they perform important roles.
A limited amount of information is available on HCMV
lncRNAs. RNA2.7 prevents the apoptosis of infected cells by
interacting directly with GRIM-19 of mitochondrial complex I
and thereby preventing its stress-induced relocalization (Reeves
et al., 2007). However, the 800 nt at the 5′ end of RNA2.7
(known as p137) are sufficient to confer neuroprotection in
vitro in a rat model of Parkinson’s disease, and it is possible
that RNA2.7 has additional functions (Kuan et al., 2012). The
RNA2.7-complex I interaction is also involved in maintaining
high levels of ATP production during infection (Reeves et al.,
2007). There is evidence that RNA4.9 can tether components
of the polycomb repression complex to the HCMV major
immediate early (IE) promoter (MIEP), resulting in decoration
of the associated histones with repressive marks (Rossetto et al.,
2013). Suppression of the MIEP by RNA4.9 would lead to
downregulation of the two major IE genes (IE1 and IE2), which
are important mediators of lytic infection, and thus promote
the maintenance of latent infection in a role analogous to
that of HSV-1 LAT. RNA5.0 is spliced, and the intron from
its ortholog (RNA7.2) in murine cytomegalovirus (MCMV) is
exceptionally long-lived and is thought to be a virulence factor
responsible for viral persistence in the salivary gland (Schwarz
et al., 2013; Schwarz and Kulesza, 2014). The present study
focuses on RNA1.2, which is an unspliced transcript encoded
by an early gene that is strongly expressed during productive
infection in a number of different cell types (fibroblasts, dendritic
cells and macrophages) at late times during infection (Gatherer
et al., 2011; Van Damme et al., 2016). We have investigated the
functional contribution of this lncRNA to HCMV infection by
studying RNA1.2 deletion mutants. Multiple cellular genes were
dysregulated in mutant-infected cells late in infection, of which
Tumor protein p63-regulated gene 1-like protein (TPRG1L) was
identified as the most highly upregulated. Our results indicate
that inhibition of TPRG1L expression by RNA1.2 during HCMV
infection plays a role in suppressing upregulation of IL-6 by
preventing NF-κB activation.
MATERIALS AND METHODS
Cell Culture
Human fetal foreskin fibroblasts (HFFF2 cells; European
Collection of Authenticated Cell Cultures, 86031405) and human
embryonic kidney cells (293T cells; American Type Culture
Collection, ATCC CRL-3216) were passaged every 3–4 days
by trypsinization. The cells were maintained at 37◦C and 5%
(v/v) CO2 in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/ml
penicillin and 100µg/ml streptomycin. Immortalized human
fibroblasts [HFT cells; Lu and Everett, 2015] were cultured in
the same manner with the addition of 50µg/ml hygromycin B.
The absence of mycoplasma from cell cultures was confirmed
by frequent testing using the MycoAlert mycoplasma detection
kit (Lonza).
Viruses
Bacterial artificial chromosome (BAC) recombineering was
employed to generate two deletion mutants (1RNA1.2 and
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1TATA) of HCMV strain Merlin [RCMV1111; GenBank
accession KM192298.1 Stanton et al., 2010] as described
previously (Warming et al., 2005; Stanton et al., 2008, 2010;
Murrell et al., 2013). Strain Merlin contains two non-functional
genes (RL13 and UL128) in order to ensure stable propagation
in fibroblast culture. Briefly, a KanR/RpsL/lacZ selectable cassette
flanked by sequences adjacent to the region to be deleted was
transfected into Escherichia coli SW102 containing the Merlin
BAC. Homologous recombination was induced to cause the
cassette to be inserted into the Merlin BAC in place of the
sequence to be deleted, and recombinant clones were positively
selected using kanamycin. Clones lacking both the region to be
deleted and the selectable cassette were then negatively selected
using streptomycin. In relation to the strain Merlin genome
sequence (GenBank accession AY446894.2), the sequences
deleted were as follows: 1RNA1.2, 6833-7862; and 1TATA,
7806-7811. To reconstitute infectious viruses, Merlin BAC DNA
and the two mutant BAC DNAs were transfected separately
into HFFF2 cells using the Basic Nucleofector kit for primary
mammalian fibroblasts (VPI-1002, Lonza) and electroporation
program T-16. The entire genome sequences of the resulting
viruses were determined by Illumina sequencing as described
previously (Murrell et al., 2016). The sequence data demonstrated
the absence of mutations other than those intended, and also
confirmed the lack of mycoplasma contamination.
Growth Curves
Six-well plates containing confluent monolayers of HFFF2 cells
were incubated for 2 h with the parental virus derived from the
Merlin BAC [termed wild-type (WT)], 1RNA1.2 or 1TATA at
a specific multiplicity of infection (MOI; quantified in plaque-
forming units/cell), and each well was replenished with 2ml fresh
medium. Subsequently, 1ml medium was removed from each
well every 2–3 days and centrifuged at 500 g for 10min to pellet
cells and debris, and 900 µl cell-free supernatant was stored
at −70◦C. The cells and debris were resuspended gently in the
remaining 100 µl medium and replaced into the well with 1ml
fresh medium. Collected supernatants were thawed briefly and
titrated in duplicate on HFFF2 cells by plaque assay.
Transcriptomic Analysis
Six-well plates containing confluent monolayers of HFFF2 cells
were infected with WT, 1RNA1.2 or 1TATA (MOI = 5) for
2 h, washed once with fresh medium, and replenished with
fresh medium. At 4, 24, or 72 h p.i., the cells were lysed
in Trizol (Invitrogen), and total cell RNA was purified using
a Direct-zol kit (Zymo Research) incorporating the DNase
digestion step. Sequencing libraries were prepared using a
TruSeq R© Stranded mRNA Library Prep kit (cat no. 20020594,
Illumina) and sequenced on an Illumina NextSeq500 using 1
× 75 nt high-output kits. The results from three independent
experiments were analyzed, from which >91.2% of reads were
high quality (>Q30). The reads were processed using Trim
Galore v0.4.2.0 (https://github.com/FelixKrueger/TrimGalore),
which removes adapter sequences from reads and filters out low
quality reads (<Q20).
Viral Transcriptomic Analysis
Individual alignments were made of the processed reads to the
sequences of the four major lncRNAs and the 170 individual
protein-coding regions in the Merlin genome, using Bowtie
2 v2.3.5 (Langmead and Salzberg, 2012). The reads in each
alignment were sorted into those originating from sense
transcripts and those originating from antisense transcripts,
using an in-house script (SamSplit) (Wignall-Fleming et al.,
2019), and realigned with the relevant sequence. The alignments
were inspected using Tablet v1.14.11.07 (Milne et al., 2010). To
compare viral transcript levels in cells infected withWT and each
of the mutants, reads per kilobase per mapped viral million reads
(RPKM) were calculated (Mortazavi et al., 2008) after omitting
the RNA1.2 reads. The R software Limma was then used to
determine changes in viral gene expression levels in mutant-
infected cells compared toWT-infected cells, and those for which
q < 0.05 (which is the p-value adjusted for the false discovery
rate using the Benjamini-Hochberg method) were considered
significant (Gentleman et al., 2004; Ritchie et al., 2015).
To determine the level of RNA1.2 expression, the number
of RNA1.2 reads was normalized to the total number of reads.
RNA1.2 abundance was then calculated relative to that of WT at
72 h p.i.
Cellular Transcriptomic Analysis
Tophat2 v2.1.1 (Kim et al., 2013) was used to align the reads to
the human genome sequence (version GRCh37; hg19, https://
grch37.ensembl.org/Homo_sapiens/Info/Index). Transcript
levels and their differences in mutant-infected cells compared to
WT-infected cells were calculated using Cufflinks/Cuffdiff v2.2.1
(http://cole-trapnell-lab.github.io/cufflinks/install/) (Trapnell
et al., 2012). The q value for each gene was determined as
described for the viral transcriptome, and transcripts for which q
< 0.05 were considered to be significantly differentially expressed
in mutant-infected cells compared to WT-infected cells.
Proteomic Analysis
Confluent HFFF2 cells in T25 flasks were infected with
WT, 1RNA1.2 or 1TATA (MOI = 5) as described for the
transcriptomic experiments. At 72 h p.i., the cells were subjected
to whole-cell proteomic analysis as described previously
(Nightingale et al., 2018). Briefly, proteins were reduced and
alkylated, and digested into peptides with Trypsin and LysC.
After enrichment, peptide samples were labeled with orthogonal
tandem-mass tags and quantified by MS3 mass spectrometry.
Proteins that were significantly differentially expressed in
mutant-infected cells compared to WT-infected cells were
identified using Benjamini-Hochberg corrected Significance B
values (Cox and Mann, 2008; Fielding et al., 2017), and results
for which p< 0.05 were considered statistically significant.
Reverse Transcription-PCR (RT-PCR) and
Quantitative PCR (RT-qPCR)
HFFF2 cells were cultured in the absence of FBS for 48 h prior to
infection with WT, 1RNA1.2 or 1TATA (MOI = 5). The cells
were lysed at 72 h p.i. using Trizol, and total cellular RNA was
purified using a Direct-zol kit incorporating the DNase digestion
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step. The QuantiTect Virus +ROX Vial kit (Qiagen) was used
for quantitative mRNA analysis by multiplexed one-step real-
time PCR, with thermal cycling performed using the Applied
BiosystemsTM 7500 real-time PCR system (Thermo Fisher).
Primer and probe sequences were as follows: TPRG1L (primers
CTGTGTCAGTTGGAAAGC and CACGTAGGTCTCGAT
GAG; probe CAGGATCAGCACGCCATTCG) and GAPDH
(primers GGAAGCTTGTCATCAATG and CCCCACTTGATT
TTGGAG; probe ATCACCATCTTCCAGGAGCGAG). Relative
RNA abundance was determined using a standard curve,
and TPRG1L mRNA levels were normalized to that of the
housekeeping GAPDH transcript. Negative controls (lacking
reverse transcriptase or lacking template RNA) were always
performed. For IL-6 and GAPDH RT-PCR, reverse transcription
was performed using the GoScript system (Promega) with
oligo d(T) primer. PCR was then performed using Phusion
High-Fidelity DNA polymerase (New England BioLabs) in the
manufacturer’s HF buffer with primers for IL-6 (CTAGATGC
AATAACCACCCC and TGACCAGAAGAAGGAATGC),
TPRG1L (CTGTGTCAGTTGGAAAGC and CACGTAGG
TCTCGATGAG), CXCL1 (GAGCATCGCTTAGGAGAAGT
and TTGTTCTAAGCCAGAAACACTG), MCP-1 (ACTCCACA
ACCCAAGAATC and CAAAACATCCCAGGGGTA), and
GAPDH (GAGTCAACGGATTTGGTCGT and TTGATTTT
GGAGGGATCTCG).
Immunoblotting
Cells were lysed in Laemmli buffer (Laemmli, 1970). Proteins
were separated by electrophoresis in precast 4–20% (w/v)
polyacrylamide TGX gels (Bio-Rad) and transferred to
polyvinylidene fluoride (PDVF) membranes (Thermo
Scientific) using the MiniPROTEAN Tetra system (Bio-
Rad). Non-specific interactions were blocked using 5% (v/v)
FBS in phosphate-buffered saline (FBS-PBS) for 1 h at room
temperature with agitation. Immunoblotting was performed
using primary antibodies against TPRG1L (ab184153, Abcam;
1:1000 dilution, or ab103650, Abcam; 1:100) and actin (A1978,
clone AC-15, Sigma; 1:4,000) in FBS-PBS containing 0.1%
(v/v) Tween 20. Membranes were incubated with fluorophore-
conjugated secondary antibodies against rabbit (35568, Thermo
Fisher; 1:10,000) or mouse (SA5-35521, Invitrogen; 1:10,000)
immunoglobulin G (IgG) in a solution of PBS-FBS containing
0.1% (v/v) Tween 20. Target proteins were visualized using an
Odyssey CLx instrument (LI-COR Biosciences).
Flow Cytometry
Flow cytometry was performed as described previously (Wang
et al., 2018). Briefly, adherent cells were harvested with TripLE
Express (Thermofisher), stained in PBS containing 1% (v/v)
BSA at 4◦C with relevant antibodies, and fixed with 4%
(w/v) paraformaldehyde. Data were collected using an Accuri
flow cytometer (BD Biosciences) and analyzed using FlowJoTM
software. The antibodies used were anti-TNFR1(CD120a)-
FITC (MBL; clone H398), anti-TNFR2(CD120b)-PE (Miltenyi
Biotec; clone REA520) and anti-HLA-I-AF647 (Biolegend; clone
W6/32); all at 1 µl/sample in 100 µl staining buffer.
TPRG1L Knockdown Cell Lines
293T cells were transfected with pLKO lentivirus vector (Moffat
et al., 2006) containing a non-targeting short hairpin RNA
(shRNA; SHC202, Sigma) or an shRNA against TPRG1L
(TRCN0000243281, Sigma) alongside the 18.9 and pVSV-g
plasmids using Lipofectamine 3000 (Sigma). Infectious lentivirus
was harvested 48 h after transfection and used to transduce
immortalized HFT cells. Puromycin selection was used to
identify and maintain shRNA-expressing transduced cells.
IL-6 Enzyme-Linked Immunosorbent Assay
(ELISA)
Confluent HFFF2 or shRNA-expressing HFT cells in 12-well
plates were serum-starved for 48 h and then infected with
WT, 1RNA1.2 or 1TATA (MOI = 5). At 72 h p.i., the
medium was replaced with either fresh medium, fresh medium
containing 10 ng/ml TNF-α (Peprotech) or 10µM IKKα-and-
IKKβ inhibitor BMS-345541 (ApexBio; see below for details),
and incubated for a further 6 h. The supernatant was cleared
by centrifuging at 5,000 g for 5min, and cell-released IL-6 was
detected in the supernatant using the Human IL-6 Quantikine
immunoassay (R&D Systems) and quantified using a standard
curve constructed using purified recombinant IL-6 provided in
the kit. The supernatants frommutant-infected cells were diluted
fivefold prior to the ELISA assay in order to reduce the IL-6
concentration to levels within the limits of the standard curve.
BMS-345541 is a highly selective inhibitor of IKKα and IKKβ
with an IC50 of 4µM and 0.3µM, respectively, in cell-free
assays (Burke et al., 2003). Binding studies suggest that the
inhibitor binds to similar allosteric sites on the IKK catalytic
subunits that affect the active sites differently (Burke et al.,
2003). Previous work in human lung fibroblasts (MRC5 cells)
and human foreskin fibroblasts (AG01523 cells) have shown
that 10µM BMS-345541 is an effective concentration (Charni
Chaabane et al., 2014).
RESULTS
Construction of RNA1.2 Mutants and
Characterization of Growth Kinetics
To investigate the role of RNA1.2, two deletion mutants were
constructed by modifying the Merlin BAC using markerless
recombineering techniques. In 1RNA1.2, the deleted region
extended from 50 nt upstream of the RNA1.2 TATA sequence
[CATAAA; (Gatherer et al., 2011)] to a position 50 nt upstream
of the polyadenylation site, which is shared with upstream genes
RL8A and RL9A (Gatherer et al., 2011). In 1TATA, only the
RNA1.2 TATA sequence was deleted, in an effort to ablate
RNA1.2 expression while preserving other functional elements in
the vicinity.
The properties of WT, 1RNA1.2 and 1TATA were assessed
in growth curve experiments, in which the release of infectious
virions from infected HFFF2 cells was measured over time.
There were no differences between growth kinetics of WT and
mutant viruses in single-step (MOI = 1) or multi-step (MOI
= 0.01) growth experiments (Figure 1). These results showed
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FIGURE 1 | Growth curves of WT and RNA1.2 mutants. HFFF2 cells were infected with WT, 1RNA1.2 or 1TATA at (A) MOI = 1 or (B) MOI = 0.01 for 2 h, after which
the medium was replenished. At each time point, the medium was replaced with fresh medium, which was harvested and titrated for cell-free infectious virus by
plaque assay in duplicate. The results of one of three independent experiments are shown. Error bars denote standard deviation values. PFU, plaque-forming units.
that RNA1.2 does not play a role in viral replication or virion
production and release in fibroblast cell culture.
Transcriptomic and Proteomic Analyses of
RNA1.2 Mutant-Infected Cells
The effects of RNA1.2 mutations on the expression of viral and
cellular genes during infection of HFFF2 cells were investigated.
The transcriptomes of cells infected with WT, 1RNA1.2 or
1TATA were analyzed using Illumina sequencing at a range of
time points throughout infection, and significant differences were
identified from three independent experiments. At 4 h p.i., no
viral transcripts were differentially expressed by the mutants in
comparison with WT (Supplementary Table 1 and Figure 2A).
At 24 and 72 h p.i., one (RL8A) and two viral genes (RL8A and
US26), respectively, were significantly differentially expressed
by 1RNA1.2, although the changes were modest (<3-fold). In
contrast, no viral genes were differentially expressed by 1TATA
at these time points (Figure 2A). In WT-infected cells, RNA1.2
was present at 4 h p.i. and at increased levels at 24 and 72 h p.i.
(Figure 2B). 1RNA1.2-infected cells did not express RNA1.2,
but 1TATA expressed it at 12, 6, and 8% of WT levels at 4,
24, and 72 h p.i., respectively, despite the absence of the TATA
sequence. Alignment of sequence reads derived from 1TATA
RNA to the viral genome indicated that this was largely a
result of residual transcription initiating in the vicinity of the
RNA1.2 promoter, whereas transcriptional readthrough from
upstream genes contributed minimally. Nonetheless, the results
indicate that RNA1.2 had a minimal effect on the expression of
viral transcripts.
At 4 h p.i., there was also no difference in the expression
of cellular transcripts in mutant-infected cells in comparison
with WT-infected cells. However, at 24 h p.i., 31 and 47
cellular transcripts were differentially expressed in 1RNA1.2-
and1TATA-infected cells, respectively, in comparison with WT-
infected cells, of which 22 were common to both mutants
(Figure 2C; Supplementary Table 2). At 72 h p.i., 1,179 and 653
cellular transcripts were differentially expressed in 1RNA1.2-
and 1TATA-infected cells, respectively, in comparison with
WT-infected cells, of which 469 were in common (Figure 2C;
Supplementary Table 2). These results indicate that RNA1.2
regulates the expression of multiple cellular transcripts, although
the changes were generally moderate (<4-fold). The increase
in the number of dysregulated cellular transcripts in mutant-
infected cells as infection proceeded was consistent with the
accumulation of RNA1.2 likely leading to more pervasive
regulatory effects. The 22 cellular transcripts dysregulated by
both mutants at 24 h p.i. were not differentially expressed by both
mutants at 72 h p.i. (Supplementary Table 2), suggesting that
RNA1.2 may regulate different cellular genes at different stages
of infection.
The proteomes of cells infected with WT, 1RNA1.2 or
1TATA were analyzed in a single multiplexed experiment. A
published strategy was employed, utilizing tandem mass tag
labeling of peptides followed by MS3 mass spectrometry for
quantitation (Nightingale et al., 2018). The transcriptomic data
had shown that RNA1.2 was expressed at a high level and
exerted its greatest regulatory effects at 72 h p.i. Therefore,
this time point was used for the proteomic analysis and all
subsequent experiments. A total of 7749 cellular and 115
viral proteins were quantified, and 657 and 665 proteins,
respectively, were differentially expressed in 1RNA1.2- and
1TATA-infected cells in comparison with WT-infected cells
(p < 0.05; Supplementary Figure 1; Supplementary Table 3).
Of these proteins, 217 cellular and 13 viral proteins were
consistently differentially expressed in 1RNA1.2- and 1TATA-
infected cells (Supplementary Table 3). These data suggested
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FIGURE 2 | Dysregulation of viral and cellular transcripts in RNA1.2 mutant-infected cells. HFFF2 cells were infected with WT, 1RNA1.2 or 1TATA at MOI = 5. RNA
was harvested at 4, 24, and 72 h p.i., and polyadenylated transcripts were subjected to transcriptomic analysis. The results of three independent experiments are
shown. (A) Scatter plots showing expression of all viral genes in the mutant transcriptomes compared to the WT transcriptome. Changes are shown as log2 fold
(log2FC) values. Transcripts that were significantly differentially expressed (q < 0.05) in the mutants are highlighted in orange and listed in the Table. (B) Graph showing
RNA1.2 abundance in WT- and RNA1.2 mutant-infected cells at 4, 24 and 72 h p.i. Values for mutants are normalized to those for WT at 72 h p.i. Error bars denote
standard deviation values. (C) Venn diagrams enumerating cellular transcripts that were significantly dysregulated in RNA1.2-infected cells (blue shading) and
1TATA-infected cells (red shading) compared to WT-infected cells (q < 0.05). Dysregulated cellular mRNAs that are unique or common to 1RNA1.2- and
1TATA-infected cells are denoted by regular and bold font, respectively.
that RNA1.2 regulates the expression of multiple proteins at late
times during infection.
Regulation of TPRG1L by RNA1.2
We used two orthogonal measurement strategies to focus
on genes consistently dysregulated by both mutants. A total
of 76 cellular genes were consistently dysregulated across all
transcriptomic and proteomic experiments (Figure 3; Table 1;
Supplementary Table 4). All were upregulated in mutant-
infected cells, and were therefore downregulated by RNA1.2. This
large number suggested that RNA1.2may have pleiotropic effects,
intervening in common pathways to reduce the expression of
multiple genes. In both 1RNA1.2- and 1TATA-infected cells,
the most upregulated gene was Tumor protein p63-regulated
gene 1-like protein (TPRG1L; also known as Mover; Figure 3;
Table 1).
The effects of RNA1.2 on TPRG1L expression were verified
in additional experiments. RT-qPCR analysis at 72 h p.i. showed
that TPRG1L transcripts were upregulated >10-fold in mutant-
infected cells compared to WT-infected cells, and >6-fold
compared to mock-infected cells (Figure 4A). Similarly, in
immunoblotting experiments, expression of TPRG1L protein was
elevated in1RNA1.2- and1TATA-infected cells, in comparison
with mock- and WT-infected cells (Figure 4B).
The function of TPRG1L is not well-understood. This protein
has been studied predominantly in mouse models, where it
has been described as a vertebrate-specific presynaptic vesicle
protein that is differentially abundant across the central nervous
system (Kremer et al., 2007; Wallrafen and Dresbach, 2018).
In human cell culture systems, TPRG1L has been described as
an activator of the NF-κB pathway, via which it can mediate
TNF-α-stimulated release of IL-6 (Liu et al., 2019). Therefore,
we hypothesized that downregulation of TPRG1L by RNA1.2
inhibits the upregulation or release of TNF-α-induced IL-6 by
infected cells. Since the ligands for TNF-α (TNFR1 and TNFR2),
have both been shown to be modulated by HCMV infection
(Browne et al., 2001; Le et al., 2011; Montag et al., 2011; Weekes
et al., 2014), we first examined whether RNA1.2 influences
surface expression of these receptors. No significant differences
for either surface TNFR1 or TNFR2 were observed between
WT- and mutant-infected cells (Figure 5A), indicating that any
alterations in TNF-α-induced cytokine production were likely to
have been due to alterations in intracellular signaling pathways.
In further support of this, treatment of WT- and mutant-infected
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FIGURE 3 | Dysregulation of cellular transcripts and proteins in RNA1.2 mutant-infected cells. HFFF2 cells were infected with WT, 1RNA1.2 or 1TATA at MOI = 5 and
analyzed at 72 h p.i. For examination of the cellular transcriptome, RNA was extracted from infected cells and polyadenylated transcripts were subjected to
transcriptomic analysis. The results of three independent experiments are shown. For examination of the cellular proteome, whole cell lysate was harvested and
analyzed in a single mass spectrometry experiment. Cellular genes were identified on the basis of consistent dysregulation in 1RNA1.2- and 1TATA-infected cells, as
assessed by both transcriptomics and proteomics. (A,B) Differential expression data for all 76 genes dysregulated in both 1RNA1.2- and 1TATA-infected cells. FC,
fold change.
TABLE 1 | Dysregulation of cellular transcripts and proteins in RNA1.2 mutant-infected cells.
Transcript Protein
1RNA1.2 1TATA 1RNA1.2 1TATA
Gene FC q-value FC q-value Gene FC p-value FC p-value
TPRG1L 3.83 0.002 3.02 0.003 TPRG1L 2.59 0.0005 2.15 0.0005
RAB14 2.88 0.002 2.33 0.003 RAB14 1.33 0.049 1.36 0.049
API5 2.56 0.002 2.12 0.003 API5 1.27 0.049 1.30 0.049
RRP1B 2.55 0.002 1.93 0.003 RRP1B 1.72 0.010 1.53 0.001
UBFD1 2.43 0.002 2.28 0.003 UBFD1 1.38 0.049 1.24 0.049
PPP4R1 2.42 0.002 1.92 0.003 PPP4R1 1.24 0.049 1.26 0.049
TSPYL5 2.29 0.002 1.81 0.003 TSPYL5 1.65 0.010 1.43 0.010
SUMF1 2.22 0.002 2.17 0.003 SUMF1 1.32 0.049 1.25 0.049
RMI2 2.21 0.002 1.95 0.003 RMI2 1.44 0.049 1.50 0.049
CTNNBIP1 2.16 0.002 1.99 0.003 CTNNBIP1 1.42 0.049 1.40 0.049
OSBPL10 2.15 0.002 1.69 0.003 OSBPL10 1.68 0.049 1.60 0.049
GRB2 2.14 0.002 1.89 0.003 GRB2 1.34 0.049 1.16 0.049
PROSC 2.12 0.002 1.92 0.003 PROSC 1.22 0.049 1.16 0.049
ATXN7L3B 2.11 0.002 1.68 0.003 ATXN7L3B 1.58 0.049 1.47 0.049
USP10 2.09 0.002 1.68 0.003 USP10 1.52 0.010 1.34 0.010
FUBP3 2.08 0.002 1.70 0.003 FUBP3 1.61 0.010 1.47 0.010
TMEM87A 2.08 0.002 1.79 0.003 TMEM87A 1.53 0.049 1.31 0.049
GLOD4 2.05 0.002 1.72 0.003 GLOD4 1.35 0.010 1.32 0.010
ELOVL5 2.01 0.002 1.76 0.003 ELOVL5 1.31 0.049 1.28 0.049
MT1F 1.98 0.002 2.12 0.003 MT1F 1.29 0.049 1.41 0.049
Cellular genes were identified on the basis of consistent dysregulation in 1RNA1.2- and 1TATA-infected cells, as assessed by both transcriptomics and proteomics. Details of the 20
most dysregulated genes are listed. FC, fold change.
cells with TNF-α resulted in modestly increased levels of both IL-
6 transcript and secreted protein (<2-fold for extracellular IL-6)
in WT-,1RNA1.2-, and1TATA-infected cells (Figures 5B,C).
However, overall IL-6 production was robustly increased in
mutant-infected cells even in the absence of TNF-α treatment
(Figures 5B,C). The transcriptome analysis did not identify IL-
6 transcripts as being dysregulated in mutant-infected cells
(Supplementary Table 2), but RT-PCR experiments showed
that they were expressed minimally in WT-infected cells and
at much higher levels in mutant-infected cells (Figure 5B).
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FIGURE 4 | TPRG1L transcript and protein levels in RNA1.2 mutant-infected cells. HFFF2 cells were infected with WT, 1RNA1.2, or 1TATA at MOI = 5. At 72 h p.i.,
RNA and protein were harvested and analyzed. (A) RT-qPCR data from three independent experiments, each with duplicates. Standard errors are marked by error
bars. Significant differences are marked by asterisks (p < 0.001, paired t-test; p < 0.05, Wilcoxon matched-pairs signed rank test). (B) Immunoblotting data from one
of three independent experiments.
FIGURE 5 | Expression of TNF receptors and IL-6 by RNA1.2 mutant-infected cells. (A) HFFF2 cells were mock-infected or infected with WT, 1RNA1.2, or 1TATA at
MOI = 5. At 72 h p.i., cell surface expression of TNFR1 and TNFR2 was detected by antibody staining and quantified by flow cytometry. Iso, isotype control of
mock-infected cells. Infection of the cells was confirmed by monitoring downregulation of cell surface HLA-I (HLA-A, HLA-B, and HLA-C). (B,C) Levels of IL-6
transcript and secreted protein in RNA1.2 mutant-infected cells. HFFF2 cells were infected with WT, 1RNA1.2 (11.2) or 1TATA at MOI = 5. At 72 h p.i., the cells were
incubated with fresh medium lacking (NT) or containing TNF-α for a further 6 h. The medium was harvested, and RNA was also isolated from the infected cells. -RT,
control lacking reverse transcriptase. (B) RT-PCR data from one of three independent experiments. (C) ELISA data for release of IL-6 into the medium from three
independent experiments, each with duplicates. Error bars denote standard error values, and asterisks mark statistically significant differences (p < 0.0001, paired
t-test; p < 0.05, Wilcoxon matched-pairs signed rank test).
Similarly, measurement by ELISA of IL-6 secretion into the
medium between 72 and 78 h p.i. showed that 1RNA1.2- and
1TATA-infected cells secreted 22- and 34-fold higher levels
of IL-6, respectively, than WT-infected cells (Figure 5C). Both
inhibitor blocking of NF-κB activity and TPRG1L knockdown
reduced extracellular release of IL-6 from 1RNA1.2- and
1TATA-infected cells, whereasWT-infected cells were unaffected
(Figures 6A–C). The lower level of IL-6 secretion in these
experiments may have be due to the use of different cell lines:
immortalized HFT cells were used to generate stable knockdown
cell lines, whereas primary HFFF2 cells were used for all other
experiments. Nevertheless, these results suggest that TPRG1L
triggers activation of NF-κB in RNA1.2 mutant-infected cells
independently of the TNF pathway and may represent a more
fundamental control of NF-κB. Consistent with this hypothesis,
the expression levels of MCP-1(CCL2) and CXCL1, which are
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FIGURE 6 | IL-6 secretion by RNA1.2 mutant-infected cells after NF-κB inhibition or TPRG1L knockdown. (A) HFFF2 cells were mock-infected or infected with WT,
1RNA1.2 or 1TATA at MOI = 5. At 72 h p.i., the cells were incubated with fresh medium lacking (NT) or containing IKKα-and-IKKβ inhibitor BMS-345541 (IKKi) for a
further 6 h. The medium was harvested, and secreted IL-6 was analyzed by ELISA. (B) Immortalized HFT cells were transduced with lentiviruses encoding a
non-targeting shRNA negative control (Neg) or a TPRG1L-targeting shRNA (KD). After the establishment of stably expressing cell lines, the cells were infected with
WT, 1RNA1.2 or 1TATA at MOI = 5. The cells were incubated with fresh medium between 72 and 78 h p.i., which was then harvested and analyzed for secreted IL-6
by ELISA. RNA was also isolated at 78 h p.i. and analyzed by RT-qPCR in (C). (C) Expression of TPRG1L mRNA in knockdown samples calculated relative to that of
Neg samples. Data from four independent experiments are shown in each of (A–C). The error bars denote standard error values, and significant differences are
marked by asterisks (p < 0.003, paired t-test; p < 0.05, Wilcoxon matched-pairs signed rank test). (D) MCP-1 and CXCL1 transcript levels were monitored during
infection of HFFF2 cells with WT, 1RNA1.2 or 1TATA at MOI = 5. At 72 h p.i., the cells were incubated with fresh medium lacking or containing TNF-α for an
additional 6 h. RNA was then harvested and analyzed by RT-PCR. The data are representative of three experiments.
also upregulated by NF-κB, mirrored that of IL-6 expression
in WT and RNA1.2-mutant-infected cells, but, unlike the IL-
6 trancript, TNF-α treatment did not influence their transcript
levels (Figure 6D).
DISCUSSION
RNA1.2 was one of the first HCMV transcripts to be identified
(McDonough et al., 1985; Hutchinson and Tocci, 1986), and,
like the other HCMV lncRNAs, it is very highly conserved
among viral strains (Davison et al., 2013; Sijmons et al., 2015;
Suárez et al., 2019). However, its contribution to infection has
remained elusive. The fact that the 1RNA1.2 and 1TATA
mutants did not display growth defects in fibroblasts indicates
that RNA1.2 does not play a critical role in the central processes
of virus production, including entry, genome replication, and
virion assembly and egress. However, the transcriptomic and
proteomic analyses indicated that this lncRNA modulates
the expression of multiple cellular genes. There was a large
degree of concordance in the results obtained using 1RNA1.2
and 1TATA, even though the latter expressed RNA1.2-like
transcripts at approximately 10% of WT levels. Nonetheless,
transcripts that were differentially expressed during 1RNA1.2
infection compared to WT infection but were more sensitive
to residual RNA1.2 expression might not have been identified
during 1TATA infection. The observation that the genes most
consistently dysregulated by the mutants at both the transcript
and protein levels were all upregulated indicates that RNA1.2
may function as a transcriptional repressor, potentially via a
common mechanism. It is also possible that more than one
mechanism is used, each requiring a specific region of RNA1.2. A
useful first step in subsequent studies would be to study separately
the first 270 nt (68% G+C) and the remainder of the sequence
(38% G+C).
In the transcriptomic and proteomic experiments, the
TPRG1L gene was identified as the most dysregulated in RNA1.2
mutant-infected cells. In subsequent experiments, TPRG1L
expression was shown to be significantly higher in RNA1.2
mutant-infected cells compared to WT-infected cells and mock-
infected cells. In additional experiments, the levels of IL-
6 transcript and secreted protein were also much higher in
RNA1.2 mutant-infected cells. Failure to identify the IL-6 gene as
dysregulated in the transcriptomic analysis (in which 1RNA1.2
upregulated IL-6 by only 1.5-fold (q = 0.08) at 72 h p.i.)
highlights a known limitation of this approach. In previous
studies using RT-qPCR data as a reference, transcriptomic
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screens detected approximately 85% of differentially expressed
genes, largely regardless of the bioinformatic algorithms used
(Costa-Silva et al., 2017; Everaert et al., 2017). Some genes
were consistently missed, and these were typically smaller and
contained fewer exons; characteristics possessed by the IL-6
gene. Our results indicate that transcriptome screens may be less
sensitive than qPCR at detecting differential expression of IL-6,
thus suggesting that not all differentially expressed genes may
have been identified by transcriptomic analysis. Consistent with
this, the levels of TPRG1L mRNA were shown to be increased
by 3.83-fold at 72 h p.i. in the transcriptomic analysis but by
>10-fold by qPCR analysis.
The data indicate that RNA1.2 acts to circumvent acute
antiviral responses by downregulating TPRG1L, which would
otherwise activate NF-κB and stimulate expression and secretion
of pro-inflammatory mediators such as IL-6. IL-6 has been
established as a critical contributor to host defense through its
stimulation of acute-phase responses, haematopoiesis, antibody
and effector T-cell responses (Tanaka et al., 2014). It has also
been shown to drive activation-induced cell death of natural
killer (NK) cells and therefore impairment of anti-viral NK cell
responses during the early stages of MCMV infection (Stacey
et al., 2017). The latter finding and the involvement of IL-6
as an important driver of HCMV reactivation from latency in
immature dendritic cells (Reeves and Compton, 2011) suggests
that this activity would be detrimental to the virus if it were to
occur early in the lytic cycle. However, the effect was observed
only late in infection, when most HCMV-encoded immune
inhibitors are expressed (Weekes et al., 2014; Patel et al., 2018).
Considering the roles that IL-6 plays in immune responses
and reactivation from latency, confirming whether RNA1.2
performs the same function during infection of other cell types,
especially immune cells such as macrophages and dendritic cells,
would be worthwhile. Previous observations regarding MCP-1
downregulation during late times of infection (Jarvis et al., 2006;
Hamilton et al., 2013; Naing et al., 2015) were also observed, and
identified RNA1.2 as the sole or major contributor to this effect,
which is likely to be driven at least in part by its downregulation
of TPRG1L.
IL-6 secretion by the RNA1.2 mutants after TPRG1L
knockdown remained higher than WT levels, suggesting
that RNA1.2 may regulate IL-6 secretion using mechanisms
additional to TPRG1L. Our transcriptomic analysis identified
RNA1.2 as downregulating PIM1 (Nihira et al., 2010) and
upregulate SEMA3A (Sumi et al., 2018), which have been
reported to activate and suppress, respectively, NF-κB signaling
in other cell types and contexts, and thus may contribute to
RNA1.2 stimulated increase in IL-6 levels. However, the screen
also identified RNA1.2 as downregulating six other potential
inhibitors of NF-κB: RCAN1 (Chen et al., 2017), IFRD1(Micheli
et al., 2011), HBEGF (Mehta and Besner, 2005), SDC1 (Zhang
et al., 2016), TSC22D3 (Di Marco et al., 2007) and PTGS1 (Wang
et al., 2019). Their modulation of NF-κB is likely to be contextual
to cell type and biological process, and thus further work will
be required to determine whether they influence NF-κB activity
during infection.
The complexity of the interplay between HCMV infection
and the NF-κB signaling pathway has been recognized previously
and is further illuminated by the present study. HCMV encodes
multiple agonists and antagonists of NF-κB, presumably as
a means of tailoring NF-κB activity to optimize infection
(Hancock and Nelson, 2017). A block in NF-κB signaling late
in infection has been reported (Jarvis et al., 2006; Montag
et al., 2006; Hancock and Nelson, 2017), but the mechanism
by which this occurs has not been identified. The present study
shows that RNA1.2 contributes to this block. Finally, as has
been demonstrated for another HCMV lncRNA (RNA2.7) that
regulates cellular functions (Kuan et al., 2012), it may prove
possible to exploit the activity of RNA1.2 in developing therapies
of IL-6-associated illnesses such as chronic inflammation and
auto-immunity (Tanaka et al., 2014).
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